Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6.37M | $580K | $2.19M | $5.12M | $4.07M | $898K | $397K | $911K | $1.34M | $1.27M |
| Revenue growth | — | -90.9% | 277.9% | 133.3% | -20.4% | -77.9% | -55.8% | 129.5% | 47.6% | -5.5% |
| Gross profit | — | $218K | $82.0K | $132K | $115K | $113K | $194K | $442K | $733K | $619K |
| Gross margin | — | 37.6% | 3.7% | 2.6% | 2.8% | 12.6% | 48.9% | 48.5% | 54.5% | 48.7% |
| Operating income | -$2.91M | -$2.05M | -$1.79M | -$4.64M | -$6.86M | -$8.72M | -$15.4M | -$11.6M | -$9.80M | -$7.45M |
| Operating margin | -45.6% | -354.0% | -81.6% | -90.8% | -168.6% | -971.5% | -3886.1% | -1270.1% | -728.5% | -585.8% |
| Net income | -$2.81M | -$1.87M | -$1.79M | -$4.10M | -$7.32M | -$8.81M | -$15.0M | -$11.5M | -$13.0M | -$7.12M |
| Net margin | -44.1% | -321.7% | -81.4% | -80.1% | -179.6% | -981.2% | -3782.4% | -1263.0% | -966.5% | -560.3% |
| EPS (diluted) | -$0.17 | -$0.07 | -$0.06 | -$0.13 | -$0.19 | -$0.21 | — | — | -$0.22 | -$0.09 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$158K | -$1.39M | -$1.93M | -$3.33M | -$8.68M | -$10.8M | -$7.46M | -$7.05M | -$5.20M | -$4.79M |
| Capital expenditures | $122K | $146K | $136K | $15.0K | $4.39M | $1.47M | $236K | $310K | $138K | $112K |
| Free cash flow | -$280K | -$1.54M | -$2.07M | -$3.35M | -$13.1M | -$12.3M | -$7.70M | -$7.36M | -$5.34M | -$4.91M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $1.49M | $538K | $1.66M | $25.6M | $7.26M | $14.5M | $10.5M | $3.20M | $1.20M | $405K |
| Total assets | $18.9M | $11.3M | $10.9M | $34.5M | $29.0M | $35.9M | $26.8M | $17.2M | $9.90M | $8.75M |
| Total liabilities | $4.91M | $3.93M | $2.79M | $893K | $2.45M | $3.06M | $2.94M | $2.27M | $2.58M | $2.42M |
| Long-term debt | $801K | $452K | — | — | $0.00 | $276K | $144K | $141K | $137K | $134K |
| Shareholders' equity | $13.5M | $7.36M | $8.06M | $33.6M | $26.5M | $32.8M | $23.9M | $14.9M | $7.32M | $6.33M |
| Retained earnings | -$50.1M | -$52.0M | -$53.8M | -$58.1M | -$65.4M | -$74.1M | -$89.2M | -$101M | -$114M | -$121M |
| Shares (wtd avg diluted) | 16.4M | 25.7M | 27.9M | 35.4M | 39.5M | 42.0M | 50.0M | 52.6M | 58.8M | 76.5M |
Every figure is extracted from IGC Pharma, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.